Rome V Process: Gastroenterology | May 2026

The Rome V process represents the most rigorous methodological evolution in the history of the Rome Foundation and marks a major conceptual maturation in how disorders of gut–brain interaction (DGBI) are defined, classified, and managed. Compared with Rome IV, Rome V is not simply a criteria revision; it is a full conceptual modernization of DGBI, integrating updated pathophysiology, evidence-based diagnostic refinement, stigma-sensitive terminology, and a stronger biopsychosocial therapeutic framework.

1. Rome V Reframes DGBI as a Positive, Biology-Based Clinical Entity

The most fundamental conceptual advance in Rome V is the continued and complete transition away from the older term “functional gastrointestinal disorders (FGID)” toward “disorders of gut–brain interaction (DGBI)”, with Rome V explicitly recommending that FGID should no longer be used.

This is one of the most important changes in the Rome V process because it directly addresses the long-standing stigma associated with the term “functional,” which historically implied:

non-organic disease,

psychosomatic illness,

psychiatric illness,

or illegitimate symptoms.

Rome V fully adopts DGBI as the preferred term because it is:

more biologically accurate,

more mechanistically grounded,

less stigmatizing,

and more acceptable to patients, clinicians, regulators, and industry.

This change is not semantic—it is foundational. Rome V explicitly frames DGBI as disorders arising from measurable disturbances in:

motility,

visceral sensitivity,

mucosal/immune function,

gut microbiota,

and central nervous system processing.

This is the core scientific identity of Rome V.

2. Rome V Is the Most Evidence-Driven Rome Iteration to Date

Rome V was developed over 7 years (2019–2026) by 144 international experts from 27 countries across 25 committees, making it the largest and most rigorous Rome effort to date.

A major methodological advance is that Rome V moved even further away from consensus-only expert opinion and toward prospective and retrospective evidence synthesis, using consensus only when evidence was insufficient.

Compared with prior Rome iterations:

earlier Rome versions were largely consensus-based,

Rome IV introduced stronger evidence requirements,

Rome V applies the most stringent evidence threshold yet.

This is one of the most important process-level changes in Rome V and strengthens the scientific legitimacy of the criteria.

3. Rome V Officially Shifts From Research Criteria to Clinical Criteria

One of the most practice-changing methodological innovations in Rome V is the explicit distinction between:

Rome V research criteria, and

Rome Foundation clinical criteria.

This is a major advance because Rome acknowledges that strict research thresholds are often too rigid for real-world clinical practice.

Rome V recognizes three major limitations of standard Rome research criteria:

A. Subdiagnostic Symptom Burden Is Clinically Real

Rome V highlights that a large proportion of patients have clinically meaningful GI symptoms but do not meet full Rome criteria.

A major global study cited in Rome V showed:

41.4% met formal Rome criteria,

33.4% had no GI symptoms,

but nearly 25% had clinically important “subdiagnostic” GI symptoms.

These patients still had:

impaired quality of life,

higher anxiety/depression,

greater healthcare use,

and significant work/life burden.

Rome V therefore explicitly recognizes that these patients still warrant diagnosis and treatment.

B. Symptom Overlap Is the Rule, Not the Exception

Rome V formally recognizes that multiple overlapping DGBI are common and clinically important, rather than confounding noise.

This is a major clinical advance because patients frequently present with overlapping:

esophageal,

gastroduodenal,

bowel,

and centrally mediated pain disorders.

Rome V emphasizes that overlapping DGBI are associated with:

worse symptom severity,

greater psychosocial burden,

poorer quality of life,

more medical utilization.

This is highly clinically relevant and improves real-world applicability.

C. “Bothersomeness” Is Elevated as a Clinical Standard

Rome V introduces bothersomeness as a formal clinical principle.

This is one of the most clinically important practical changes in the entire document.

Rather than relying rigidly on research-style duration/frequency thresholds, Rome V states that in clinical care, diagnosis is justified when:

symptom quality matches the Rome phenotype,

organic disease is sufficiently excluded,

and symptoms are sufficiently bothersome to impair life or prompt care-seeking.

This is a major real-world improvement and makes Rome V far more clinically usable.

4. Rome V Reinforces Positive Diagnosis Over Diagnosis by Exclusion

Rome V strongly reinforces one of the Rome Foundation’s most important philosophical contributions: DGBI should be diagnosed positively, not merely by exclusion.

This remains a central Rome principle, but Rome V strengthens it further through:

updated symptom-based criteria,

stepwise diagnostic algorithms,

selective testing,

and physiology-supported phenotyping.

The major practical implication is clear: clinicians should not pursue endless exclusionary testing once a positive DGBI diagnosis is established and alarm features are absent.

5. Rome V Expands the Role of Diagnostic Algorithms

Rome V formalizes diagnostic algorithms for all DGBI categories and integrates them into the 3rd edition of Rome V Diagnostic Algorithms for Common GI Symptoms.

This is a major methodological advance because Rome criteria alone define syndromes, but algorithms now provide:

structured evaluation pathways,

symptom-to-test sequencing,

rational exclusion of mimics,

and more reproducible clinical decision-making.

This is one of the most clinically actionable changes in Rome V.

6. Rome V Strengthens the Multidimensional Clinical Profile (MCP)

Rome V explicitly acknowledges that diagnosis alone is insufficient for management and strengthens the Multidimensional Clinical Profile (MCP) as a central clinical framework.

This is a major practical and conceptual advance because Rome V emphasizes that treatment must be individualized using:

symptom phenotype,

physiologic mechanisms,

psychosocial comorbidity,

illness severity,

quality-of-life burden,

and healthcare impact.

This is one of the clearest statements in Rome V that DGBI care must move beyond diagnosis into structured personalized phenotyping.

7. Rome V Deepens the Biopsychosocial Model

The biopsychosocial conceptual model remains the intellectual core of Rome V and is more robustly developed than in Rome IV. The diagram on page 8 explicitly maps the interaction among early life factors, psychosocial factors, physiology, DGBI presentation, and outcomes, emphasizing bidirectional brain–gut signaling rather than linear causality.

This remains one of the most important conceptual strengths of Rome V.

Rome V strengthens mechanistic integration of:

early life influences,

psychosocial stress,

visceral hypersensitivity,

immune activation,

microbiome,

food/diet,

autonomic dysfunction,

and central pain modulation.

The key message is that DGBI are not “psychological disorders” and not merely “motility disorders”; they are multisystem disorders of integrated gut–brain dysregulation.

8. Rome V Makes the Therapeutic Relationship Part of Treatment

One of the most clinically important but often underappreciated Rome V advances is the explicit positioning of the therapeutic relationship as treatment.

Rome V devotes a full section to the 12 steps to enhance the therapeutic relationship, emphasizing that clinician behavior directly affects:

symptom severity,

healthcare utilization,

treatment adherence,

quality of life,

and outcomes.

This is a major practical advance and one of the strongest reaffirmations in Rome V that communication is not ancillary—it is therapeutic.

9. Rome V Formalizes Severity-Stratified Care

Rome V more explicitly links treatment intensity to illness severity and formalizes a mild–moderate–severe framework for DGBI management.

This is clinically important because it aligns treatment with disease burden:

Mild: education, reassurance, diet/lifestyle

Moderate: symptom monitoring, targeted pharmacotherapy, brain–gut behavioral therapy

Severe: neuromodulators, structured psychosocial care, multidisciplinary DGBI referral

This is one of the most clinically practical therapeutic frameworks in Rome V.

Clinical Bottom Line

The Rome V process is not merely a criteria update—it is a full modernization of DGBI science and clinical care. Its most important advances are:

full replacement of FGID with DGBI,

strongest evidence-based Rome methodology to date,

separation of research vs clinical criteria,

recognition of subdiagnostic and overlapping DGBI,

formal use of bothersomeness in clinical diagnosis,

expanded diagnostic algorithms,

stronger multidimensional clinical profiling,

deeper biopsychosocial integration, and

formal recognition that the therapeutic relationship itself is part of treatment.

The single most important Rome V process advance is this: DGBI are now framed not as diagnoses of exclusion, but as positive, biology-informed, clinically actionable disorders requiring structured biopsychosocial care.